DB05797ExperimentalProtein Based Therapies
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
- Mechanism
- Curator reviewed
TNX-901 is an anti-IgE antibody. IgE antibody is the receptor responsible for allergic reactions and severe asthma attacks. An anti-IgE antibody binds IgE and prevents it from initiating an allergic reaction.
- Primary indication
- Investigated for use/treatment in allergic reaction.Curator reviewed
- Code names
- TNX-901
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Talizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account